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Summary
Homocystinuria due to cystathionine p-synthase (CS) deficiency is 
the most common inborn error of methionine metabolism, Patients with 
CS-deficiency have an extremely high risk of vascular disease. The 
underlying mechanism is still unsolved. Dysfunction of endothelial 
cells could be the trigger in the formation of atherosclerosis and throm­
bosis, Therefore, differences in cell function were studied between nor­
mal and CS-deficient human umbilical endothelial cells (HUVECs). 
Total homocysteine (tHcy) concentrations in culture media as a meas­
ure of homocysteine export increased in all cell lines, including the 
cell line with CS-deficiency, with constant amounts of approximately 
2.5 (jlM every 24 h. von Willebrand factor (vWF), tissue plasminogen 
activator (tPA) and plasminogen activator inhibitor (PAI-1) in culture 
media were used as markers of endothelial function and increased also 
with progression of culture time. The effects of additions of folate, 
vitamin B6 and methionine to the culture medium were studied. The 
homocysteine export and the markers of endothelial function did not 
differ between the control and the CS-deficient HUVECs under various 
test conditions, These data show that CS-deficient endothelial cells 
have normal homocysteine export and normal endothelial cell function. 
In CS-deficient patients the very high blood levels of homocysteine, 
probably due to deficient CS function in liver and kidney, seems to be 
the hazardous factor to endothelial cells, thus promoting atherosclerosis 
and thrombosis in CS-deficient patients,
introduction
Deficiency of cystathionine p-synthase (CS) resulting in very low or 
absent enzyme activity is an autosomal recessively inherited disorder of 
methionine metabolism and causes high levels of homocysteine in 
blood (hyperhomocysteinemia) and in urine (homocystinuria). Clini­
cally, the most life-threatening complications of homocystinuria are 
severe atherosclerosis or thrombosis at young age. Homocystinuria is 
treated with vitamin B6 (pyridoxine) as first choice; approximately 
50% of patients with homocystinuria respond to this vitamin treatment 
with a decrease of the homocysteine levels. Vitamin B6 non^respond- 
ing patients could be treated with betaine, folic acid, vitamin B12, or
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even methionine restriction (1), The most common mutation in the CS- 
gene among Dutch homocystinuric patients is the T833C transition (2). 
Patients homozygous for this transition respond very well to vitamin B6 
therapy (3).
The underlying mechanism causing vascular disease in hyperhomo­
cysteinemia is still unsolved. In vitro high levels of homocysteine can 
generate H20 2 and free radicals are formed which in vivo theoretically 
could result in increased lipid peroxidation (4 ,5), causing accumulation 
of oxidised low density lipoprotein inside the vessel wall. However, in 
homocystinuric patients no increased lipid peroxidation had been found
(6, 7).
The first step in the development of atherosclerosis or thrombosis is 
dysfunction of endothelial cells. Elevated levels of von Willebrand fac­
tor (vWF), plasminogen activator inhibitor (PAI-1), and tissue plasmi­
nogen activator (tP A) are considered as markers of endothelial dysfunc­
tion (8-10). To study the hypothesis, that homocysteine itself can cause 
endothelial cell dysfunction, endothelial cells have been cultured with 
additions of various concentrations of homocysteine to the culture 
medium (11-14). However, these studies used very high concentrations 
of homocysteine (1 to 10 mM) in its reduced form (i.e. with free SH- 
group), which is highly unphysiologic. In blood only 1% of total homo­
cysteine is present in its reduced form. This means that applying 10 inM 
reduced homocysteine in vitro is about 50,000 times higher than the 
concentration normally present in blood of patients with mild hyper­
homocysteinemia (15).
In vitro lymphoma cells, liver cells, and fibroblasts exported homo­
cysteine into the extracellular medium (16-18). Enhanced homocys­
teine export is associated with increased homocysteine production or 
inhibition of metabolism (19). In our previous study with human umbil­
ical vein endothelial cells (HUVECs) we showed a strong dependency 
of the homocysteine export on folic acid levels in the culture medium. 
No effects of additions of other vitamins involved in homocysteine 
metabolism, such as vitamin B6 and vitamin B 12, were observed (20). 
Because increased homocysteine export reflects an imbalance in the 
homocysteine metabolism, we concluded that endothelial cells are vul­
nerable to subnormal folate levels. The underlying mechanism for this 
phenomenon is not known, but this imbalance in the homocysteine 
metabolism is likely influenced by activities of key enzymes in homo­
cysteine remethylation (methylene tetrahydrofolate reductase: MTHFR 
and methionine synthase: MS) and transsulfuration (CS) (Fig. 1).
In the present study the homocysteine export of HUVECs of a CS- 
deficient patient homozygous for the T833C transition is compared 
with the export of normal HUVECs. The influence of additions of 
folinic acid [5-formyl-THF (tetrahydrofolate)], vitamin B6 (pyridoxine 
HC1), and methionine is explored. Changes in endothelial cell function 
are studied by measurements of vWF, tPA, and PAI-1 in culture media.
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Fig. 1 Homocysteine 
CS = cystathionine 
MTHFR = methylene tetrahydrofolate 
reductase, MS = methionine synthase, 
THF = tetrahydrofolate. CS uses py- 
ridoxal phosphate and MS methyl 
cobalamin as co-factor
Materials and Methods
Cell Culture
Endothelial cells from the human umbilical vein (HUVECs) were obtained 
from umbilical cords of healthy fetuses from uncomplicated pregnancies and 
deliveries of healthy mothers (non-smoking and without medication). Within 
24 h after cord collection endothelial cells were isolated by collagenase (Worth­
ington, New Jersey, USA) treatment according to the procedure of Jaffe et at. 
(21). HUVECs were cultured under standard conditions of which more details 
were described in our previous article (20). All HUVEC experiments were 
performed in 12-well plates with cells of 3 days in confluence in the third or 
fourth passage.
After the experiments the cells were counted by using the methylene blue 
(3,7-bis(dimetylamino)phenothiazine-5-ium chloride) cell counting method ac­
cording to Oliver et al. (22). This method is based on the ability of methylene 
blue to bind electrostatically at pH 8.5 to negatively charged groups inside the 
cell, mostly phosphate moieties of nucleic acids. The stained cells were eluted 
with 1:1 (v/v) ethanol>0.1 M HC1 and optical density was read at wavelength 
620 nm with Titertek Multi sc an 340 CC (ICN Flow, Irving, Scotland). Before 
it was used in routine, a linear function between the optical density and cell 
number was established.
All experiments with normal HUVECs were performed in duplo with at 
least three different cell lines. All experiments with CS deficient HUVECs were 
performed in triplo.
Homocysteine Analysis
Homocysteine concentrations were measured by an automated high perfor­
mance liquid chromatography (HPLC) melhod with reverse phase separation 
and fluorescent detection (Gilson 232-401 sample processor, Spectra Physics 
8800 solvent delivery system and Spectra Physics LC 304 fluorometer) (23). 
The detection limit was 0.5 |jlM. The intra- and inter run variation coefficient 
was <5%,
Cystathionine /3-synthase (CS) Assay
CS activities were measured following the procedure described by Fowler 
et al. (24). The determination was carried out in the presence or absence of
Pyridoxal-5-Phosphate and the final product I4C-cystathionine was measured 
radiochemically. Protein concentrations were determined by the method of 
Lowry et al, (25).
DMA An alysis
Genomic DNA was isolated from HUVECs and polymerase chain reaction 
(PCR) was performed with 100 ng of genomic DNA. The PCR product was 
subjected to Bsd and the restriction fragments were detected and visualized 
according the procedure described by Kluijtmans et al. (2).
ELISAs
a) von Willebrand factor (vWF): vWF antigen was determined by a sandwich 
ELISA modified from Ingerslev et al. (26). In brief: 96-well plates (Nunc, 
Roskilde, Denmark) were coated with rabbit anti-human vWF polyclonal 
antiserum (A082; Dako A/S, Denmark). The reference line was made from dilu­
tions of unincubated standard culture medium to washing buffer (PBS, 0.05% 
Tween 20 [ICN Flow, Irving, Scotland], and 0.5 mg/ml BSA [Sigma Chemical 
Co, St Louis, USA]). Blanks were standard culture medium without serum. Test 
samples were diluted 1:80 by washing buffer. After incubating and washing 
rabbit anti-human vWF peroxidase conjugate (P226; Dako A/S, Denmark) was 
applied. After incubating and washing the substrate solution (20 /xl of 0.05 M 
citric acid and 0.1 M Na2HP04 pH 5.0,40 mg ortho-diphenylalanine [OPD], and 
20 fxl 30% H20 2) was added. The reaction was stopped with 50 fxl/well of 2 M 
H2S04. The optical density was measured at wavelength 492 nm by Titertek 
Multiscan 340 CC. Measurements were performed in triplo or duplo.
b) Tissue plasminogen activator (tPA) and plasminogen activator inhibitor I
4
(PAM): tPA and PAM antigen were measured with a commercial kit (Biopool 
Imulyse tPA, PAI-1, Umea, Sweden) according to the procedure of the manu­
facturer. The tPA assay detects single- and two-chain tPA in complex with anti- 
plasmin, PAM, and PAI-2. The PAM assay detects active and latent PAI-1, 
whereas tPA/PAI-1 and uPA/-PAI-l complexes are poorly detected.
Statistics
*
Data are expressed in mean and standard deviation. The mean and standard 
deviation of experiments with the CS-deficient cell line was calculated from 
results from at least three different experiments. The mean and standard devia­
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tion of the control cell lines was calculated from the means of at least three dif­
ferent control cell lines. The value obtained from a control cell line is the mean 
(without a standard deviation) of a duplo culture experiment of this cell line. 
Statistical analyses were performed with the t-test and p <0.05 was considered 
statistically significant.
Results
Characterisation of the HUVECs Deficient in Cystathionine 
/¡•synthase (CS)
In 6 different HUVECs from healthy controls and in the HUVECs 
from a patient with CS-deficiency (a sister of a CS-deficient patient 
homozygous for the T833C transition) the CS-activity was measured 
with and without addition of pyridoxal-5-phosphate to the enzyme 
assay mixture (Table 1). The mean enzyme activity of the six controls 
with and without pyridoxal-5-phosphate was 6.9 and 5,6 nmol 
cystathionine/h/mg protein respectively. The enzyme activity of the 
CS-deficient cell line with and without pyridoxal-5-phosphate was
0.88 and 0.18 nmol cystathionine/h/mg protein respectively (Table 1). 
The CS-activities of the control HUVECs were comparable with those 
observed in cultured normal fibroblasts and the CS-activity of the 
CS-deficient cell line was within the range of cultured fibroblasts of 
CS-deficient patients (2),
Genomic DNA was isolated from HUVECs of the CS-deficient 
patient and homozygosity for the T833C transition was demonstrated. 
This mutation is the most common cause of CS-deficiency in Dutch 
homocystinuria patients (2).
Homocysteine Export
7. Standard Conditions and the Effect o f Folinic Acid Supplementation
Under standard culture conditions HUVECs exported a fairly con­
stant amount of homocysteine into the culture medium despite normal 
folate levels in the medium (20).
Table 1 CS-activities in nmol cystathionine per h per mg protein of six 
normal HUVECs and one CS-deficient HUVEC
Cystathionine 
nmol/h/mg protein 
(-PLP)
Cystathionine 
nmol/h/mg protein 
(+PLP)
HUVEC
control (n=6)
mean 5.60 6.90
(range) (3,1-10.9) (3.1-15)
HUVEC
patient 0.18 0.88
The mean (± SD) homocysteine export in four different normal 
HUVECs under standard culture conditions after 24, 48, and 72 h o f 
culture was 1.74 (± 0.68), 4.04 (± 1.23) and 6.40 (± 1.71) \xM respec­
tively. Addition of 3 ,30, and 100 nM folinic acid (a stable precursor of 
MeTHF) to the standard culture medium reduced the homocysteine 
export in a dose-dependent manner (Table 2).
The mean homocysteine export of the CS-deficient HUVECs under 
standard culture conditions after 24,48, and 72 h of culture was in the 
range as observed in normal HUVECs. Furthermore addition of folinic 
acid in various concentrations showed the same dose dependency as 
observed in normal HUVECs (Table 2).
When the homocysteine export was expressed in amount homocys­
teine per cell (pmol/cell) the CS deficient HUVECs showed also export 
in the range of normal HUVECs (Table 3).
Vitamin B12 supplementation to the standard culture medium 
(M199 did not contain Vitamin B12) did not result in differences in 
homocysteine export in similar experiments (data not shown).
2. Pyridoxine HCl Additions
Standard culture medium contained 200.5 nM pyridoxine according 
to the manufacturer. The homocysteine export did not show differ** 
ences between standard culture medium and the media with additions 
of 0.3, 1, 10, 100, 1000 |iM pyridoxine. No differences were found 
between control HUVECs and CS deficient HUVECs (Table 4).
When homocysteine export was expressed in homocysteine per 
amount of cells (pmol/cell) in normal and CS deficient HUVECs, also 
no differences were found under conditions as mentioned above (data 
not shown).
PLP <= pyridoxal phosphate
3. Methionine Loading
The homocysteine export was studied under various concentrations 
of methionine additions to the culture medium of normal and CS-defi­
cient HUVECs,
Methionine deficient conditions of the culture medium were 
achieved by using M l99 without methionine. In these experiments the 
only source of methionine to the culture medium was derived from the 
20% serum which resulted in a methionine concentration of 5 jxM in the 
culture medium. Under these conditions the homocysteine export was 
very low: in normal HUVECs the mean (± SD) of the homocysteine 
export after incubations of 24,48, and 72 h was 0.6 (± 0.5), 1.2 (± 0.6), 
and 2.1 (± 0.9) jxM respectively. In CS-deficient HUVECs similar 
results were obtained (Table 4).
After additions of methionine in the culture medium (0, 5, 10, 50, 
100, 200 jjlM) the homocysteine export increased. This increase was
Table 2 At culture times of 24, 48, 
and 72 h homocysteine export in cul­
ture medium of normal and CS-defi- 
cient HUVECs was measured after 
additions to medium of folinic acid of 
0,3,30, and 100 nM
24 hours 
tHcy (¿imol/1) 
mean (±SD )
48 hours 
tHcy (/xniol/1) 
mean (±SD )
72 hours 
tHcy (/ttnol/I) 
mean (± S D )
normal CS-deficient normal CS-deficient normal CS-deficicnt
folinic acid 
(nmol/1)
0 1.7 1.4 4.0 4.0 6.4 6.5
(±  0.7) (±  0.3) (±  1.2) (±  0.2) <± 1.7) ( ±  0.3)
3 1.2 0.7 2.9 2.5 4.2 4.8
(±  0.9) (±  0.8) (±  0.9) (±  0.2) C± 1.0) (±  0.6)
30 0.6 0.5 1.6 0.6 2.2 2.5
(±  0.3) (±  0.1) (±  0.7) (±  0.4) ( ±  0.9) <± 0.4)
100 0.2 0.4 1.5 1.1 2.2 1.8
(±  0.2) (±  0.1) (±  0.8) (±  0.2) ( ±  1.1) ( ±  0.4)
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24 hours
tHcy/cell ((pmolj4-pmol0)/tfcells) 
mean (±SD)
48 hours
tHcy/cell ((pmol4i-pmoU/#ce!ls) 
mean (±SD)
72 hours
tHcy/cell ((ptnol^-pmolj/^cells) 
mean (±SD)
normal CS-deficient normal CS-deficient normal CS-deficient
folinic add 
(nmol/1)
•
0 6.9 5.4 8.8 9.7 14.78 14.54
(±  2.7) (±  1.1) (±  2.1) (±  0.2) (± 3 .47) (±  0.01)
3 4.0 2.9 6.0 5.4 9.02 10.29
(±  1-2) (± 3 .2 ) (±  0.9) (±  0.4) (±  1-72) (±  0.87)
30 2,0 1.7 3.3 1.3 4.61 5.27
(±  1.1) (±  0.3) (±  1.0) (±  0.8) ( ±  1.72) (±  1.22)
100 -0.1 1.6 2.9 2.4 4.49 3.68
( ± 2.5) (±  0.2) (±  1.8) (±  0.5) (±  2.06) (±  0.65)
Table 3 At culture times of 24, 48, 
and 72 h homocysteine export ex­
pressed per amount of cells in culture 
medium of normal versus CS-deficient 
HUVECs was measured after addi­
tions to medium of folinic acid of 0,3, 
30, and 100 nM
dose dependent with maximal homocysteine export of approximately
2 (jlM per 24 h at a methionine addition of 50 \M  or more. Under all
k
conditions studied, no differences could be seen between normal and 
CS deficient HUVECs (Table 4). Again no difference was found if the HUVECs (Table 5).
Under standard culture conditions the mean (± SD) concentration of 
vWF increased slightly. The results of vWF measurements in culture 
media of CS-deficient HUVECs were similar to those of normal
homocysteine export was expressed per cell (data not shown).
4. von Willebrand Factor (vWF)
In the culture medium of normal and CS-deficient HUVECs, vWF 
was measured in culture medium after various additions of folinic acid 
(0 ,3 ,30 , and 100 nM) at various culture times (24,48, and 72 h).
Additions of 3 ,30 and 100 nM folinic acid to the culture medium of 
normal HUVECs did not result in significant changes of vWF concen­
trations compared with the results obtained by using standard culture 
medium alone* vWF levels in various culture media of CS-deficient 
HUVECs were similar to normal HUVECs (Table 5).
Similar results were obtained when vWF concentration in culture 
medium was expressed per cell (data not shown).
24 hours 
tHcy (/imol/1) 
mean (±SD)
48 hoars 
tHcy (firnol/l) 
mean (±SD)
72 hours 
tHcy (ptmol/1) 
mean (±SD)
normal CS-deficient normal CS-deficient normal CS-deficient
Pyridoxine HCJ 
(/¿mol/l)
0 2.4 2.7 4.5 4.6 5.4 6,1
(±  0.9) (±  0.4) (±  0.7) (±  0.2) (± 0.9) (±  0.3)
0.3 2.8 2.6 4.3 4.4 6.4 6.2
(± 0.4) (±  0.3) (±  0.8) (±  0.5) (± 0.5) (±  0.8)
1 2.7 3.0 4.6 4.2 5.7 5.9
(± 0.4) (±  0. 1 ) (± 0.9) (±  0.6) (± 1 .0) (±  0.2)
10 2.6 2.9 4.0 4.8 û 5.8 5.7
(± 0.8) (±  0 .2) (± 0-5) (± 0.6) (±  0.5) (±  0.5)
100 2.5 2.6 4.0 4,4 5.6 6.1
(± 0.5) (±  0 .6) (± 1 .0) (± 0.9) (± 0 .6) (±  0.4)
1000 2.1 2.6 4.3 4.3 6.2 6.4
(± 0.5) (£  0.2) (± 0.9) (± 0 .0) (± 0.S) (±  0. 1 )
Table 4 At culture times of 24, 
48, and 72 h homocysteine ex­
port in culture medium of normal 
and CS-deficient HUVECs was 
measured after additions to me­
dium of pyridoxine HC1 of 0, 
0.3,1,10,100, and 1000 fxM  and 
in methionine free M l99 with 
additions of methionine of 0, 5, 
10,50,100,200 jjlM
Methionine
(/¿mol/1)
0 0.6 1.5 1.2 1.8 2.1 2.3
(± 0.5) (±  0.3) <± 0.6) C± 0 .6) (±  0.9) (± 0.9)
5 1.3 2.4 2.3 3.3 3.4 4
(± 0.4) (±  0.7) (±  0.2) (± 0.7) (± 0.9) (±  1 .1 )
10 2.1 2.6 4.1 5.1 5 5.8
(±  0.6) (±  0.3) (± 0.6) (±  0.7) (± 1.3) ( ± 1 .0)
50 2.6 3.1 5.3 5.4 6.7 6.4
(± 0.5) (±  0.3) (± 1.3) (± 0.5) (± 1 .0) (± 0.9)
100 2.4 2.9 5.1 5.3 6.3 7.4
(± 0.4) (±  0. 1 ) (±  0.8) (±  0.4) (±  0.8) (±  0 .2)
200 2.5 3,1 5.1 5.8 6.6 7.3
(±  0.8) (±  o .i) (±  1 .1 ) (± 0 .6) (± 1.4) (±  0 .1 )
a
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Table 5 At culture times of 24, 
48, and 72 h vWF, tPA, and 
PAM concentrations in culture 
medium of normal and CS-defi- 
cient HUVECs were measured 
after additions of 0, 3, 30, and 
100 nM of folinic acid to 
medium
24 hours 
mean (±SD)
48 hours 
mean (±SD)
72 hours 
mean (±SD)
normal CS-deficient normal CS-deficient normal CS-deficient
vWF( % )
in medium with •
folinic acid of
(nmol/1): •
0 108 117 122 129 137 145
( ± 8) (± 5) (±  12) (± 4 ) (±  15) (± 5)
3 103 113 115 126 • 135 145
(dr 5) (± 5) (± 9 ) (± 7 ) (±  16) (± 8)
30 100 1 1 1 116 119 130 144
(± 7) (± 3 ) (±  6) (± 4 ) (± 12) <± 9)
100 107 113 116 121 138 142
(± 9) (± 7) (±  H) (±  8) (±  15) (± 10)
tPA (ng/ml) 
in medium with 
folinic acid of 
(nmol/1):
0 3.1 2.5 7.3 10.7 8.9 19.(5*
(dt 1.3) (±  0.3) (± 2 .6) (±  1 .0) (±  3.7) (± 3.0)
3 2.5 2.4 6.7 8.3 8.7 13.4
(± 0.9) (±  0.3) (± 3.0) (±  1.4) (± 4.7) (± 1 .6)
30 2.8 2.5 6.0 8.2 8.3 12.7
(± 1 .1 ) (± 0.6) (±  1.9) (±  1.7) (±  3.5) (± 2 . 1)
100 2.7
■
2,1 6.6 7.8 8,6 11.9
(± 1 .2) (± 0.5) (± 1.7) (±  0.9) (±  4.7) (± 2 .0)
PAI-1 (ng/ml) 
in medium with 
folinic acid of 
(nmoi/1):
0 452 376 938 791 1082 1092
(± 178) (± 77) (±  409) (±  194) (± 260) (± 494)
3 424 402 811 898 962 1107
(± 192)
i
(±  90) (± 272) (± 144) (±  269) (± 305)
30 414 363 861 921 898 1027
(± 160) (± 56) (±  283) (± 399) ( ± 269) (± 286)
100 564 385 904 990 1104 1212
(± 338) (±  64) (± 373) C± 547) (±  398) (± 304)
(*) Significant difference between normal and CS-deficient HUVECs in incubation medium of 72 hrs. under standard culture 
conditions. (p < 0.01).
footnote; vWF expressed in %, 100% was defined as the amount vWF in uniiicubated standard medium.
5. Tissue Plasminogen Activator (tPA)
In the culture medium of normal and CS-deficient HUVECs tPA-
Additions of the various concentrations of folinic acid to the culture 
medium at various -incubation times (see paragraph 4) showed no sig­
nificant differences in tPA concentrations between normal and CS-de-
antigen concentrations were measured under the same conditions as ficient HUVECs,
mentioned above in paragraph 4. With progression of culture time (24, 
48 and 72 h) the mean level of tPA in the culture medium increased in 
normal HUVECs (Table 5).
The results of tPA measurements in culture media of CS-deficient 
HUVECs were similar to the results of normal HUVECs. Only the tPA 
concentration in culture medium of CS-deficient HUVECs without 
folinic acid addition after 72 h was significantly elevated compared 
with tPA concentration in culture medium of normal HUVECs under 
the same conditions (Table 5).
Expression of tPA concentration per cell showed similar results 
(data not shown).
6. Plasminogen Activator Inhibitor (PAI-1 )
Under the same conditions as mentioned above in paragraph 4, 
PAI-1 antigen concentrations were measured in the culture medium of 
normal and CS deficient HUVECs. With progression of culture time 
(24, 48 and 72 h) the mean level of PAM  in the culture medium in-
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creased in normal HUVECs (Table 5). The results of PAl-1 measure­
ments in culture media of CS-deficient HUVECs were similar to the re­
sults of normal HUVECs (Table 5).
Additions of the various concentrations of folinic acid to the culture 
medium did not result in any difference in PAI-1 concentrations within 
or between the different cell lines (Table 5).
Expression of PAI-1 concentrations per cell showed similar results 
(data not shown).
The possible contribution of endothelial stress factors such as me­
chanical stress, oxidant stress or other stress factors to our results could 
not be studied. The present investigation showed that CS-deficient en­
dothelial cells have normal homocysteine export and normal endothe­
lial cell function. Therefore, in CS-deficient patients the very high 
blood levels of homocysteine, probably due to deficient CS function in 
liver and kidney, seem to be the hazardous factor to endothelial cells 
and thus promoting atherosclerosis and thrombosis in CS-deficient 
patients.
Discussion
HUVECs lacking virtually all CS-activity due to homozygosity for 
the T833C transition, showed the same homocysteine export as normal 
HUVECs. Furthermore no differences between these CS-deficient and 
normal cell lines were observed in response to additions to the culture 
medium of:
1. Folinic acid; in both the normal and the CS-deficient cell lines the References
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homocysteine export was reduced in a dose dependent manner.
2. Pyridoxine: additions of pyridoxine to the culture medium did not 
affect homocysteine export.
3. Methionine; additions of methionine (“methionine loading”) in­
creased the homocysteine export in a dose dependent manner until a 
maximal level was reached at approximately 50 fimol methionine/1. 
Again, there was no difference in response to this methionine load­
ing between the CS-deficient and the normal HUVECs.
Even under these various extreme conditions the homocysteine ex­
port did not differ between the control and the CS-deficient HUVECs, 
which suggests that CS does not contribute to the homocysteine metab­
olism in endothelial cells. Therefore the high blood homocysteine lev­
els in CS-deficient patients seem to be due to deficient CS function in 
liver and kidney. In these organs CS is expressed at a high level (27).
Also no differences between control and CS-deficient HUVECs 
were present in concentrations of vWF, tPA, and PAI-1 (markers of 
endothelial function). These concentrations increased with almost con­
stant amount in the culture medium every 24 h, which is a normal prop­
erty of cultured endothelial cells (28-30). Folinic acid addition to the 
medium, which reduced the homocysteine export, did not affect these 
endothelial cell function parameters. In this experiment again the 
CS-deficient endothelial cells were indistinguishable from normal 
HUVECs. These results indicate that not the abnormal homocysteine 
metabolism inside endothelial cells in patients with CS-deficiency is 
the hazardous factor to endothelial cells, but the high homocysteine lev­
els in the blood itself. These findings are not in line with the results of 
the study of De Groot et al. (31), who suggested that CS-deficiency 
leads to accumulation of toxic sulphur containing amino acids inside 
endothelial cells which could cause endothelial damage,
In mild hyperhomocysteinemia, a common risk factor of vascular 
disease, the mechanism might be essentially different, because hetero­
zygosity is nowadays not supposed to be present in this condition (2, 
32). Mild defects in homocysteine remethylation seem to be involved in 
mild hyperhomocysteinemia, such as homozygousity for 677C-»T 
mutation in MTHFR gene (2,32). This defect may cause an imbalance 
of homocysteine metabolism in cultured endothelial cells resulting in 
increased homocysteine export to the blood. In our former study we al­
ready demonstrated the existence of a delicate balance in homocysteine 
remethylation in endothelial cells, which was strongly influenced by 
folic acid levels in the culture medium (20). Our future studies will 
focus on the contribution of such mild defects on homocysteine remeth­
ylation of endothelial cells.
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Cytology is an essential part of gynecologic diagnosis. This bilingual atlas 
shows typical cellular pictures of the most important pathologic conditions. 
The malignant and premalignant lesions of the squamous epithelium with 
their inflammatory, degenerative and regenerative alterations as well as 
the increasingly Important changes of the glandular epithelium are 
described. The illustrations of the atlas are of special didactic value: each 
colour picture is combined with an explanatory schematic drawing for 
identification of single cells or cell elements.
This third, for the first time bilingual edition is based on the latest 
developments in gynecologic cytology; text and references are completely 
revised, several figures have been exchanged or supplemented for better 
explanation, and the new chapter of papilloma virus infection of the fe­
male genitals has been added. However, the proven systematic structure 
and excellent didactic principle have not been changed.
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